WHO launches trial of 4 potential COVID-19 treatments
22 March 2020
The World Health Organization (WHO) has launched the SOLIDARITY trial – a global mega-trial to look at 4 drugs or combinations, as potential COVID-19 treatments.
Several countries have already signed up, including Canada, France and Iran. The US and UK have not been named at this stage. Four drugs or combinations of drugs will be tested for their effectiveness in treating COVID-19.
These are remdesivir (an antiviral), lopinavir and ritonavir in combination (2 antivirals used in HIV), the lopinavir and ritonavir combination plus interferon beta, and the antimalarial drug chloroquine.
Remdesivir is an antiviral that has been trialled (unsuccessfully) to fight Ebola virus. Experimentally, it has been shown to inhibit some coronavirus infections – SARS and MERS. It stops the virus from replicating.
Lopinavir and ritonavir. Lopinavir is a protease inhibitor used in the treatment of HIV. It has been shown to inhibit the SARS virus in vitro (in a test tube). It is combined with ritonavir, which increases the length of time it is active in the body. A trial in 200 adults hospitalised with severe COVID-19 did not find any benefit of lopinavir and ritonavir over standard care.
Beta-interferon is a drug used in multiple sclerosis. It works by reducing inflammation and regulating the immune system.
Chloroquine and hydroxychloroquine
Chloroquine and its derivative hydroxychloroquine are antimalarial drugs. Hydroxychloroquine is also used to treat rheumatoid arthritis. Hydroxychloroquine has shown antiviral activity against coronaviruses in vitro and specifically against SARS-CoV-2, the virus that causes COVID-19.
As well as being effective, any potential drug treatment must also be tolerated well by patients. At the doses that might be needed to fight SARS-CoV-2, side-effects may become an issue for some drugs.
The trial is designed to be simple and easy for the participating hospitals to record data.
Last Reviewed: 23/03/2020
1. Mitja O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. [Correspondence]. Lancet Published online March 19, 2020. https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30114-5/fulltext
2. Ca B, Want Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalised with severe covid-19. NEJM 2020, March 18. https://www.nejm.org/doi/full/10.1056/NEJMoa2001282?query=featured_home
3. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 18 March 2020. https://www.nature.com/articles/s41421-020-0156-0
Novel coronavirus - COVID-19
Symptoms of COVID-19, caused by the 2019 novel coronavirus, include fever, cough and shortness of breath. Find out how to protect yourself.
Highlights from the latest research into COVID-19 and SARS-CoV-2.
Anti-parasitic drug ivermectin kills SARS-CoV-2 virus
Ivermectin, a widely used anti-parasitic drug, has been shown to kill the SARS-CoV-2 virus in cell culture.
Hepatitis C infection
People infected with hepatitis C virus can develop chronic (ongoing) infection. Treatment with antivirals can cure hepatitis C and prevent the complications of chronic infection.
COVID-19 survivors’ blood plasma may help critically ill
Critically ill patients with COVID-19 have shown improvement after transfusion of plasma from survivors of the disease.